This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riely, G. J. Articles by Ladanyi, M. Search for Related Content PubMed PubMed Citation Articles by Riely, G. J. Articles by Ladanyi, M.

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

Authors' Affiliations: ¹ Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, ² Department of Pathology, ³ Human Oncology Pathogenesis Program, and ⁴ Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York

Requests for reprints: Gregory J. Riely, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-3042; Fax: 212-794-4357; E-mail: rielyg{at}mskcc.org.

Purpose: KRAS mutations are found in 25% of lung adenocarcinomas in Western countries and, as a group, have been strongly associated with cigarette smoking. These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib.

Experimental Design: We determined the frequency and type of KRAS codon 12 and 13 mutations and characterized their association with cigarette smoking history in patients with lung adenocarcinomas.

Results: KRAS mutational analysis was done on 482 lung adenocarcinomas, 81 (17%) of which were obtained from patients who had never smoked cigarettes. KRAS mutations were found in 15% (12 of 81; 95% confidence intervals, 8-24%) of tumors from never smokers. Similarly, 22% (69 of 316; 95% confidence intervals, 17-27%) of tumors from former smokers, and 25% (21 of 85; 95% confidence intervals, 16-35%) of tumors from current smokers had KRAS mutations. The frequency of KRAS mutation was not associated with age, gender, or smoking history. The number of pack years of cigarette smoking did not predict an increased likelihood of KRAS mutations. Never smokers were significantly more likely than former or current smokers to have a transition mutation (GA) rather than the transversion mutations known to be smoking-related (GT or GC; P < 0.0001).

Conclusions: Based on our data, KRAS mutations are not rare among never smokers with lung adenocarcinoma and such patients have a distinct KRAS mutation profile. The etiologic and biological heterogeneity of KRAS mutant lung adenocarcinomas is worthy of further study.

This article has been cited by other articles:

				G. J. Riely, J. Marks, and W. Pao KRAS Mutations in Non-Small Cell Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 201 - 205. [Abstract] [Full Text] [PDF]